## CI: The Cigna Group - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 -4.4% below STRENGTH zone (3.0-6.0%). Stock is in no-man's land without clear edge. Caution: momentum weakening (-1.5% MRS).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($250.28)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 7
- **Sentiment:** Bullish (Bullish: 0, Bearish: 0)

**1. TKO Group Lifts Quarterly Dividend to $0.78 per Class A Share, Payable Dec. 30 to Holders of Record as of Dec. 15**
- Source: MarketScreener | 20251204T140858 | Somewhat-Bullish | Relevance: 70%
- TKO Group Holdings, Inc. has announced an increase in its quarterly dividend to $0.78 per Class A share. This dividend is payable on December 30, 2025, to shareholders of record as of December 15, 2025. The announcement was made on December 4, 2025, at 08:49 am EST.

**2. Investors Pack Into CVS Ahead Of Make-Or-Break Update**
- Source: Finimize | 20251203T165133 | Neutral | Relevance: 64%
- CVS Health is approaching a critical investor day, with UBS noting the stock is "long crowded and well liked" due to anticipation of a multi-year recovery. The market is focused on margin recovery in its Health Care Benefits, how Caremark handles contract renewals, and the stabilization of the Pharmacy and Consumer Wellness business. While UBS anticipates conservative guidance, any disappointment could lead to a sell-off, whereas modest positive news could reinforce confidence in CVS's turnaround.

**3. Listening to healthcare professionals: Dexcom launches new education offering, Dexcom Academy**
- Source: MarketScreener | 20251204T131053 | Somewhat-Bullish | Relevance: 64%
-  Dexcom, Inc. has announced the launch of Dexcom Academy, a new educational offering designed for healthcare professionals. This initiative reflects Dexcom's commitment to continuous glucose monitoring (CGM) education, responding to feedback from medical practitioners. The academy aims to enhance understanding and implementation of CGM technology in diabetes management.

**4. CVS Health (NYSE: CVS) reports $474B U.S. economic impact, 1.3M jobs supported**
- Source: Stock Titan | 20251205T140857 | Neutral | Relevance: 63%
-  CVS Health released its inaugural National Economic Impact Report, revealing an annual U.S. economic impact of $474 billion and supporting 1.3 million jobs nationwide. The report highlights CVS's extensive reach with 300,000+ employees, approximately 9,000 retail pharmacies, and over 1,000 clinics, serving 185 million individuals. Additionally, CVS Health contributed $58.6 billion in taxes and invested $239 million in community initiatives.

**5. T1 Energy Inc: In Nov 2025, company and executive received voluntary document request from SEC - SEC filing**
- Source: marketscreener.com | 20251205T092500 | Somewhat-Bullish | Relevance: 63%
- T1 Energy Inc. announced that both the company and an executive received a voluntary document request from the SEC in November 2025, according to an SEC filing. This news was published on December 5, 2025, and provides an update on recent activities involving the energy company.

### Analyst Activity

**Target Signal:** VERY_BEARISH (Raises: 0, Lowers: 1)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-11-12 | Bernstein | $294 | $346 | -15% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-11-12 | Bernstein | main | Market Perform |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_BUYING** |
| Buys | 2 ($1.01M) |
| Sells | 2 ($0.00M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 48.7% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 6 / 4 |

**Top Holders:**
- Vanguard Group Inc: 9.6% (+0.1%)
- Blackrock Inc.: 8.3% (-1.1%)
- JPMORGAN CHASE & CO: 5.0% (+106.4%)
- State Street Corpora: 4.5% (-1.2%)
- Price (T.Rowe) Assoc: 4.2% (+9.8%)

### Key Risks

1. Long-term trend broken: trading 12.6% below SMA200.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 0.53 indicates undervaluation relative to growth. Forward P/E 8.6x stretched relative to 4% growth. Balance sheet: $3.1B free cash flow. Analyst sentiment negative (1 target cuts vs 0 raises). Insider buying signal ($1.0M), management confidence. Institutional flow bullish (6 buying vs 4 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $70.2B |
| Beta | 0.26 |
| 52W Range | $239.51 - $350.00 |
| Short Interest | 1.9% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 0.53 |
| Forward P/E | 8.6 |
| Current P/E | 9.0 |
| YoY Growth | 3.8% |
| EPS Direction | STABLE |

### Technicals

MRS_10 deteriorating from -2.9% to -4.4% (-1.5% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 7.4pp (needs >3.0% for momentum thesis). Below SMA200 (0.87x), long-term trend not supportive. RSI neutral at 41.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | -4.40% (CS: 10) | Weak |
| RSI_14 | 41.4 | Neutral |
| MACD Histogram | 0.29 | Bullish |
| vs SMA20 | 0.979x | Below |
| vs SMA50 | 0.937x | Below |
| vs SMA200 | 0.874x | Below |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $265.44
- **Stop Loss:** $250.28 (5.7% risk)
- **Target:** $280.60 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 32
- **Position Value:** $8,494.08
- **Portfolio %:** 8.49%
- **Risk Dollars:** $500.00
- **Risk Per Trade:** 0.50%
- **Modifiers:** L1 100% | L2 50% | Combined 0.50x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | AVOID (Zone C) | 0.50x |

*NORMAL regime with moderate risk appetite persisting. Mixed earnings signals with industrial weakness (John Deere) offset by consumer/tech strength, while institutional flows show selective positioning rather than broad risk-off. Fed meeting in 9 days provides near-term catalyst but current data suggests status quo maintenance.*

### Earnings

**Next:** 2026-02-05 (Est: $7.90)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $7.64 | $7.83 | +2.5% |
| 2025Q2 | $7.15 | $7.20 | +0.6% |
| 2025Q1 | $6.35 | $6.74 | +6.2% |
| 2024Q4 | $7.82 | $6.64 | -15.1% |

---
*RULE-based L3 | 2026-01-06 16:36 | MRS_10*